Dyne Therapeutics (DYN)
(Real Time Quote from BATS)
$44.12 USD
+0.93 (2.15%)
Updated Jul 23, 2024 03:52 PM ET
After-Market: $43.99 -0.13 (-0.29%) 4:16 PM ET
2-Buy of 5 2
D Value D Growth F Momentum F VGM
Income Statements
Fiscal Year end for Dyne Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 242 | 171 | 150 | 59 | 14 |
Income After Depreciation & Amortization | -242 | -171 | -150 | -59 | -14 |
Non-Operating Income | 6 | 3 | 1 | 0 | -1 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -236 | -168 | -149 | -59 | -15 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -236 | -168 | -149 | -59 | -15 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -236 | -168 | -149 | -59 | -15 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -242 | -168 | -146 | -58 | -14 |
Depreciation & Amortization (Cash Flow) | 1 | 3 | 4 | 1 | 0 |
Income After Depreciation & Amortization | -242 | -171 | -150 | -59 | -14 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 59.68 | 51.98 | 50.90 | 14.40 | NA |
Diluted EPS Before Non-Recurring Items | -3.95 | -3.23 | -2.93 | -4.13 | NA |
Diluted Net EPS (GAAP) | -3.95 | -3.23 | -2.93 | -4.13 | NA |
Fiscal Year end for Dyne Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 69.16 | 67.68 | 62.27 | 66.74 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -69.16 | -67.68 | -62.27 | -66.74 |
Non-Operating Income | NA | 3.51 | 1.05 | 2.06 | 1.83 |
Interest Expense | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | NA | -65.65 | -66.64 | -60.21 | -64.90 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -65.65 | -66.64 | -60.21 | -64.90 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -65.65 | -66.64 | -60.21 | -64.90 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | NA | 81.04 | 61.39 | 61.11 | 59.84 |
Diluted EPS Before Non-Recurring Items | NA | -0.81 | -1.09 | -0.99 | -1.08 |
Diluted Net EPS (GAAP) | NA | -0.81 | -1.10 | -0.99 | -1.08 |